

CONTENTS

ORIGINAL CONTRIBUTIONS

INTRINSIC DEFECT IN B-LYMPHOBLASTOID CELL LINES FROM PATIENTS WITH X-LINKED LYMPHOPROLIFERATIVE DISEASE TYPE 1. I. CELL SURFACE PHENOTYPE AND FUNCTIONAL STUDIES	
<i>L.M. Shlapatska, L.M. Kovalevska, I.M. Gordiienko, S.P. Sidorenko</i>	2
GROWTH INHIBITORY AND ADJUVANT THERAPEUTIC POTENTIAL OF AQUEOUS EXTRACT OF <i>TRITICUM AESTIVUM</i> ON MCF-7 AND HeLa CELLS	
<i>A. Hussain, T.M. Gheewala, A.J. Vas, K. Shah, P. Goala, S. Khan, S. Hinduja, C. Sharma</i>	9
INVOLVEMENT OF HUMAN BETA-DEFENSIN-2 IN REGULATION OF MALIGNANT POTENTIAL OF CULTURED HUMAN MELANOMA CELLS	
<i>O. Gerashchenko, E. Zhuravel, O. Skachkova, N. Khranovska, V. Pushkarev, P. Pogrebnoy, M. Soldatkina</i>	17
USE OF XENOGENEIC VACCINE MODIFIED WITH EMBRYONAL NERVOUS TISSUE ANTIGENS IN THE TREATMENT OF B16-MELANOMA-BEARING MICE	
<i>I.M. Voeykova, N.I. Fedosova, O.M. Karaman, O.Yu. Yudina, G.V. Didenko, G.S. Lisovenko, L.M. Evstratieva, G.P. Potebnya</i>	24
DYNAMICS OF CHANGES OF ANTIOXIDANT SYSTEM INDEXES DURING THE GROWTH OF TWO LEWIS LUNG CARCINOMA VARIANTS	
<i>O.N. Pyaskovskaya, L.V. Sorokina, D.L. Kolesnik, I.V. Boichuk, O.R. Melnikov, G.I. Solyanik</i>	29
NUMBER OF LANGERHANS CELLS IS DECREASED IN PREMALIGNANT KERATOSIS AND SKIN CANCERS	
<i>Z. Shevchuk, A. Filip, V. Shevchuk, E. Kashuba</i>	34
THE CHARACTERIZATION OF IgG ANTIBODIES TO GalNAc BETA-TERMINATED GLYCANS OF GASTRIC CANCER SURVIVORS	
<i>E.P. Smorodin, B.L. Sergeev, O.A. Kurtenkov</i>	38
THE ROLE OF nt590 P21 GENE POLYMORPHISM IN THE SUSCEPTIBILITY TO NASOPHARYNGEAL CANCER	
<i>S. Soares, R. Craveiro, R. Catarino, E. Breda, R. Medeiros, I. Bravo</i>	44
SHORT COMMUNICATIONS	
ANTICANCER EFFICACY OF HYDROXYETHYLTHIAMINE DIPHOSPHATE <i>IN VIVO</i>	
<i>L. Gevorkyan, K. Gambashidze</i>	48
BIOCHIP ARRAY TECHNOLOGY AND EVALUATION OF SERUM LEVELS OF MULTIPLE CYTOKINES AND ADHESION MOLECULES IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	
<i>J.M. Horacek, T. Kupsa, M. Vasatova, L. Jebavy, P. Zak</i>	50
POINT OF VIEW	
IN SEARCH OF MOLECULAR APPROACHES TO IMPROVING CANCER THERAPY EFFICACY	
<i>E. Cherepenko, G. Telegeev</i>	52
CHRONICLE	
GRIGORIY VASILIEVICH BONDAR	56